China Regenerative Medicine International Past Earnings Performance
Past criteria checks 2/6
China Regenerative Medicine International has been growing earnings at an average annual rate of 63.4%, while the Biotechs industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 3.2% per year. China Regenerative Medicine International's return on equity is 13.5%, and it has net margins of 6.2%.
Key information
63.4%
Earnings growth rate
67.0%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 3.2% |
| Return on equity | 13.5% |
| Net Margin | 6.2% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How China Regenerative Medicine International makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 245 | 15 | 34 | 0 |
| 31 Mar 23 | 234 | 5 | 30 | 0 |
| 31 Dec 22 | 232 | 5 | 26 | 0 |
| 30 Sep 22 | 246 | 31 | 23 | 0 |
| 30 Jun 22 | 254 | 26 | 22 | 0 |
| 31 Mar 22 | 294 | 49 | 2 | 0 |
| 31 Dec 21 | 283 | 52 | 6 | 0 |
| 30 Sep 21 | 274 | -95 | 14 | 0 |
| 30 Jun 21 | 248 | -82 | -16 | 0 |
| 31 Mar 21 | 222 | -105 | 46 | 0 |
| 31 Dec 20 | 182 | -120 | 48 | 0 |
| 30 Sep 20 | 110 | -201 | 46 | 0 |
| 30 Jun 20 | 57 | -237 | 97 | 0 |
| 31 Mar 20 | 12 | -239 | 61 | 0 |
| 31 Dec 19 | 19 | -264 | 100 | 0 |
| 30 Sep 19 | 15 | -1,005 | 373 | 0 |
| 30 Jun 19 | 19 | -1,042 | 424 | 0 |
| 31 Mar 19 | 56 | -1,177 | 564 | 0 |
| 31 Dec 18 | 73 | -1,194 | 598 | 0 |
| 30 Sep 18 | 555 | -346 | 482 | 0 |
| 30 Jun 18 | 607 | -337 | 489 | 0 |
| 31 Mar 18 | 642 | -237 | 469 | 0 |
| 31 Dec 17 | 756 | -238 | 492 | 0 |
| 31 Oct 17 | 489 | -171 | 431 | 0 |
| 30 Jul 17 | 425 | -169 | 416 | 0 |
| 30 Apr 17 | 357 | -185 | 389 | 0 |
| 31 Jan 17 | 284 | -182 | 282 | 0 |
| 31 Oct 16 | 51 | -261 | 342 | 0 |
| 31 Jul 16 | 29 | -223 | 345 | 0 |
| 30 Apr 16 | 28 | -191 | 303 | 0 |
| 31 Jan 16 | 18 | -269 | 237 | 0 |
| 31 Oct 15 | 6 | -243 | 187 | 0 |
| 31 Jul 15 | 4 | -259 | 152 | 0 |
| 30 Apr 15 | 3 | -250 | 134 | 0 |
| 31 Jan 15 | 2 | -299 | 158 | 0 |
| 31 Oct 14 | 2 | -292 | 125 | 0 |
| 31 Jul 14 | 1 | -281 | 122 | 0 |
| 30 Apr 14 | 1 | -263 | 113 | 0 |
| 31 Jan 14 | 0 | -103 | 95 | 0 |
| 31 Oct 13 | 1 | -84 | 76 | 0 |
| 31 Jul 13 | 1 | -68 | 63 | 0 |
| 30 Apr 13 | 1 | -61 | 59 | 0 |
| 31 Jan 13 | 1 | -55 | 51 | 0 |
| 31 Oct 12 | 1 | -58 | 54 | 0 |
Quality Earnings: 8592 has high quality earnings.
Growing Profit Margin: 8592's current net profit margins (6.2%) are lower than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8592 has become profitable over the past 5 years, growing earnings by 63.4% per year.
Accelerating Growth: 8592's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 8592 had negative earnings growth (-42.1%) over the past year, making it difficult to compare to the Biotechs industry average (-18.6%).
Return on Equity
High ROE: 8592's Return on Equity (13.5%) is considered low.